Saturday 17 October 2026
Export UPB’s income statement to Excel — free account
Upstream Bio, Inc.
Upstream Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 million, up 20.4% from fiscal 2024. In the quarter to June 2026, revenue fell 17.5%, EPS grew 1.35% and free cash flow grew 9.33%, each against the same quarter a year earlier.
2.76
0.61
−18.10%
Follow UPB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
2.56 | 0.00 | 0.00 | 0.00 |
P/S ratio |
362.43 | 512.30 | 147.20 | 119.57 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(45.61) | (47.73) | (10.22) | (10.60) | |
P/B ratio |
2.68 | 4.30 | 1.61 | 1.39 | |
Price to Tangible BV |
2.68 | 4.30 | 1.61 | 1.39 | |
EV/Sales |
229.37 | 392.64 | 58.52 | 36.83 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.25) | (8.41) | (1.39) | (0.85) | |
EV/FCF |
(5.22) | (8.39) | (1.39) | (0.85) | |
Quick Ratio |
31.33 | 25.44 | 21.63 | 26.24 | |
Current Ratio |
32.67 | 26.15 | 23.14 | 27.99 | |
Net Debt/EBITDA |
9.82 | 7.63 | 6.65 | 6.17 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
0.66 | 0.72 | 1.18 | 0.90 | |
Capex/Depreciation |
0.59 | (0.04) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
4,827.96% | 6,013.32% | 3,536.27% | 4,668.69% | |
Selling, General and Administrative Expense of Revenue |
811.42% | 997.90% | 781.82% | 912.29% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
379.80% | 375.15% | 449.42% | 563.26% | |
Graham Net Nets |
0.37 | 0.23 | 0.62 | 0.71 | |
Graham Number |
34.03 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
38.99% | (9.83%) | (32.33%) | (41.91%) | |
Free Cash Flow Yield |
(12.11%) | (9.14%) | (28.69%) | (36.20%) | |
Revenue per Share |
0.01 | 0.01 | 0.02 | 0.01 | |
Operating CF per Share |
(0.41) | (0.57) | (0.88) | (0.65) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.41) | (0.57) | (0.88) | (0.65) | |
Cash per Share |
6.91 | 6.34 | 5.42 | 4.79 | |
Shareholders Equity per Share |
7.02 | 6.31 | 5.60 | 4.97 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.02 | 6.31 | 5.60 | 4.97 | |
Free Cash Flow |
(22.30) | (30.68) | (47.85) | (35.62) | |
Working Capital |
377.11 | 338.35 | 302.61 | 269.61 | |
Capital Expenditures |
(0.06) | (0.05) | — | — | |
Net Current Asset Value |
376.41 | 337.80 | 302.22 | 269.39 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.09 | 0.08 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.65 | 0.64 | 0.80 | 0.85 | |
Average Payables |
4.43 | 3.38 | 3.21 | 2.43 | |
Average Assets |
311.95 | 417.75 | 387.11 | 350.85 | |
Average Common Equity |
109.14 | 404.81 | 374.80 | 339.85 |
Columns are period end dates